Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Blocklisting Interim Review

14 Aug 2015 13:57

RNS Number : 1309W
ABCAM Plc
14 August 2015
 



For immediate release

14 August 2015

ABCAM PLC

("Abcam" or "the Company")

 

Block Admission Return

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:

Abcam plc

Name of scheme:

1. Abcam EMI Scheme

2. Abcam SAYE Scheme

3. Abcam 2005 Share Option Scheme

4. Abcam Share Incentive Plan

5. Abcam Company Share Option Plan

6. Abcam Long Term Incentive Plan

7. Annual Bonus Plan

Period of return:

From:

6 February 2015

To:

7 August 2015

Balance of unallotted securities under scheme(s) from previous return:

1. 560,915

2. 31,405

3. 2,660,309

4. 281,146

5. 683,238

6. 1,965,749

7. 399,479

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

1. -

2. -

3. -

4. -

5. -

6. -

7. -

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

1. -

2. -

3. 133,504

4. -

5. 53,056

6. -

7. -

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1. 560,915

2. 31,405

3. 2,526,805

4. 281,146

5. 630,182

6. 1,965,749

7. 399,479

 

Name of contact:

Laura Taylor, Investor Relations

Telephone number of contact:

01223 696000

 

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Jeff Iliffe, Chief Financial Officer

Laura Taylor, Investor Relations Manager

 

J.P.Morgan Cazenove - Nominated Adviser & Joint Corporate Broker

+ 44 (0) 20 7742 4000

James Mitford / Alex Bruce - Nominated Adviser

Peel Hunt LLP - Joint Corporate Broker

+ 44 (0) 20 7418 8900

Clare Terlouw / Jock Maxwell MacDonald - Corporate Broking

 

FTI Consulting

+44 (0) 20 3727 1000

Ben Atwell / Brett Pollard / Natalie Garland-Collins

 

Notes to Editors

 

About Abcam

Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 750 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRBDGDILUBBGUS
Date   Source Headline
17th Dec 20139:48 amRNSAdditional Listing
10th Dec 20139:38 amRNSPDMR Shareholding
3rd Dec 20139:21 amRNSDirector/PDMR Shareholding
2nd Dec 20137:00 amRNSTotal Voting Rights
26th Nov 201310:46 amRNSDirector/PDMR Shareholding
21st Nov 20139:45 amRNSHolding(s) in Company
11th Nov 201312:28 pmRNSDirector/PDMR Shareholding
8th Nov 20133:47 pmRNSResult of AGM
8th Nov 20138:56 amRNSDirector/PDMR Shareholding
8th Nov 20137:00 amRNSAGM Statement
1st Nov 20132:24 pmRNSTotal Voting Rights
29th Oct 20131:53 pmRNSHolding(s) in Company
25th Oct 20139:48 amRNSDirector/PDMR Shareholding
10th Oct 20135:40 pmRNSDirector/PDMR Shareholding
4th Oct 20132:38 pmRNSDirector/PDMR Shareholding
2nd Oct 20137:00 amRNSAnnual Financial Report
1st Oct 20137:00 amRNSTotal Voting Rights
25th Sep 20135:48 pmRNSHolding(s) in Company
24th Sep 20131:29 pmRNSDirector/PDMR Shareholding
16th Sep 201311:38 amRNSDirector/PDMR Shareholding
16th Sep 201311:33 amRNSDirector/PDMR Shareholding
10th Sep 20132:01 pmRNSDirector/PDMR Shareholding
10th Sep 20137:00 amRNSPreliminary Results
2nd Sep 20133:58 pmRNSTotal Voting Rights
27th Aug 20135:04 pmRNSDirector/PDMR Shareholding
31st Jul 20137:00 amRNSNotification of Full Year Results
30th Jul 20135:33 pmRNSHolding(s) in Company
26th Jul 20139:15 amRNSDirector/PDMR Shareholding
22nd Jul 20137:00 amRNSFull Year Trading Update
28th Jun 201312:00 pmRNSAbcam appoints Chief Marketing Officer
25th Jun 201312:54 pmRNSDirector/PDMR Shareholding
17th Jun 20134:22 pmRNSDirector/PDMR Shareholding
3rd Jun 20138:00 amRNSDirector/PDMR Shareholding
3rd Jun 20138:00 amRNSTotal Voting Rights
22nd May 20134:12 pmRNSDirector/PDMR Shareholding
16th May 20136:13 pmRNSDirector/PDMR Shareholding
3rd May 20132:15 pmRNSDirector/PDMR Shareholding
2nd May 20138:39 amRNSTotal Voting Rights
26th Apr 20133:56 pmRNSDirector/PDMR Shareholding
11th Apr 20132:21 pmRNSDirector/PDMR Shareholding
4th Apr 201311:02 amRNSHolding(s) in Company
4th Apr 201311:00 amRNSHolding(s) in Company
2nd Apr 20135:33 pmRNSTotal Voting Rights
2nd Apr 20135:19 pmRNSHolding(s) in Company
26th Mar 20135:30 pmRNSDirector/PDMR Shareholding
21st Mar 20135:30 pmRNSHolding(s) in Company
20th Mar 20137:00 amRNSHalf Yearly Report
19th Mar 20137:00 amRNSDirector/PDMR Shareholding
18th Mar 20134:41 pmRNSDirector/PDMR Shareholding
15th Mar 20135:43 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.